Abstract
The purpose of this study was to determine the potency and selectivity of the alpha-1 adrenergic receptor antagonist terazosin based on relationships between plasma concentrations and blockade of intraurethral pressure (IUP) and mean arterial pressure (MAP) responses after single dosing and to determine cumulative effects after repeated dosing. To this end, the relationships between plasma concentrations and blockade effects of terazosin on phenylephrine (PE)-induced IUP and MAP were evaluated in conscious male beagle dogs after single (0.1, 0.3 and 1 mg/kg) and repeated (0.3 and 1 mg/kg) daily oral dosing of terazosin. Blockade effects and plasma concentrations were evaluated at selected times for periods of ≤24 hr. Terazosin produced dose-dependent antagonism of PE-induced IUP and MAP responses. When IUP and MAP blockade effects were plotted against terazosin plasma concentration, direct relationships were observed that were well described by the sigmoidal maximal effect model and resulted in IUP and MAP IC50 values of 48.6 and 12.2 ng/ml, respectively. Repeated daily dosing resulted in little accumulation of terazosin in plasma and demonstrated consistent blockade responses over 7 days. MAP blockade was observed up to 23 hr after terazosin administration, whereas IUP blockade returned to control levels before 23 hr. Combined pharmacokinetic/pharmacodynamic analysis showed no selective antagonism of IUP by terazosin but may provide a useful way to show uroselectivity of novel agents.
Footnotes
-
Send reprint requests to: David Witte, D-4MN, AP10, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064.
-
↵1 Standard solutions of terazosin were prepared based on the free-base weight.
-
↵2 Prazosin concentration was based on the free-base weight.
-
↵3 Dose solutions of terazosin were prepared based on the salt weight.
-
↵4 Dose solutions of PE were prepared based on the salt weight.
- Abbreviations:
- IUP
- intraurethral pressure
- MAP
- mean arterial pressure
- PE
- phenylephrine
- BPH
- benign prostatic hyperplasia
- TFA
- trifluoroacetic acid
- HPLC
- high-performance liquid chromatography
- EDTA
- ethylenediaminetetraacetic acid
- t1/2
- terminal elimination half-life
- τ
- dosing interval
- AUC0-∞
- area under the plasma concentration-time curve
- Css,min
- trough plasma concentration at the end of the dosing interval after reaching steady state
- C1,min
- plasma concentration at the end of the first dosing interval
- CL/F
- oral plasma clearance
- F
- oral bioavailability
- Cmax
- maximal plasma concentration
- Cp
- plasma concentration
- Cn
- plasma concentration measured at the last time point
- Tmax
- time to reach maximal plasma concentration
- ke
- first order rate constant for elimination
- ka
- first order rate constant for absorption
- Rac
- accumulation index
- Emax
- maximal effect
- Emaxobs
- maximal observed effect
- TEmax
- time to reach maximal effect
- AUCE
- area under the effect-against-time curve
- ANOVA
- analysis of variance
- Received January 10, 1997.
- Accepted April 2, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|